Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Sangamo BioSciences Inc.
DescriptionZFN-mediated genome editing that runs on the In Vivo Protein Replacement Platform (IVPRP)
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationFabry's disease
Indication DetailsTreat Fabry's disease
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today